Australia markets closed

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
23.820.00 (0.00%)
At close: 04:00PM EDT
25.00 +1.18 (+4.95%)
After hours: 06:48PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close23.82
Open23.96
Bid23.51 x 100
Ask24.00 x 100
Day's range23.43 - 24.39
52-week range4.00 - 31.01
Volume186,149
Avg. volume98,858
Market cap359.339M
Beta (5Y monthly)2.25
PE ratio (TTM)N/A
EPS (TTM)-61.80
Earnings date09 Aug 2024 - 13 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est67.00
  • GlobeNewswire

    Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

    REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments. “We have continued to make stron

  • GlobeNewswire

    Jasper Therapeutics Announces Briquilimab Development Program in Asthma

    Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in Asthma on May 20, 2024, at 8:00 a.m. EDT REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven d

  • GlobeNewswire

    Jasper Therapeutics to Present at Upcoming Investor Conferences in May

    REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May: Capital One Securities Biotech/Biopharma Disruptors Even